Novartis CAN-Covid Trial on Coronavirus Patients Didn't Meet Primary, Secondary Endpoints

   By Cecilia Butini

Novartis AG said Friday that its phase 3 CAN-Covid clinical trial evaluating the safety of a monoclonal antibody in hospitalized patients with Covid-19 pneumonia and cytokine release syndrome didn't meet its primary and secondary endpoints.

The study's primary endpoint was to demonstrate that the drug, canakinumab, plus standard of care gave patients a greater chance of survival without needing mechanic ventilation. The secondary endpoint was the reduction of Covid-19-related deaths during the four-week period following treatment.

The Swiss pharmaceutical major said the drug, the commercial name of which is Ilaris, remains an effective treatment for its approved indications, which include the treatment of a number of rare auto-inflammatory diseases.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

November 06, 2020 01:57 ET (06:57 GMT)

Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024